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OBJECTIVES: Patients with unrecognized bipolar disor-
ders (UBP) are often treated for depression prior to being
correctly diagnosed, thus delaying appropriate drug
therapy. This study compared hospital use, attempted 
suicides and one-year post-treatment costs of UBP
patients relative to patients with major depressive dis-
orders (MDD) and recognized bipolar (RBP) patients.
METHODS: Data from the California Medicaid program
for the period October 1994 to January 1999 were used
to identify 25,308 adult patients who initiated a new
episode of antidepressant therapy. RBP patients received
their initial diagnosis of bipolar disorders or used mood
stabilizers on or before the initiation of antidepressant
therapy. UBP patients initiated antidepressant therapy
with an initial MDD diagnosis, then received a bipolar
disorder diagnosis or initiated mood stabilizer therapy at
a later date. Multivariate models were used to estimate
the marginal risks and costs associated with UBP patients
relative to RBP or MDD-only patients. RESULTS: RBP
and UBP patients represented 15.4% and 6.3% of all
antidepressant users, respectively. UBP patients had
higher rates of hospital use (12.5%) and attempted
suicide (0.88%) than RBP patients (11.2% and 0.29%)
or MDD patients (7.5% and 0.18%). Multivariate results
indicated that UBP patients were three times more likely
to use hospital services (p < 0.0001) and 3.2 times more
likely to attempt suicide (p = 0.0004) than MDD patients.
RBP patients were twice as likely to use hospital care (p
< 0.0001) than MDD patients. UBP was associated with
higher 1-year outpatient costs relative to RBP patients
(+$200; p < 0.05), but was not associated with higher
inpatient or total costs. RBP was associated with lower
one-year outpatient costs ($109; p < 0.05) but higher
inpatient costs ($634; p < 0.001) and total costs ($508;
p < 0.01) relative to MDD patients. CONCLUSIONS:
UBP is both common and costly. More effort is needed to
provide early and correct diagnosis, and to effectively
treat these patients.
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OBJECTIVE: This study compared treatment patterns
and costs for bipolar disorder (BP) patients (recognized
and unrecognized) to those of major depression disorder
(MDD) patients without a BP claim (non-BP) during the
observational period. METHODS: An employer claims
database (1998–2001) was used to identify 9009 patients
(aged 18–65) diagnosed with MDD and initially treated
with antidepressants (AD). A subset of patients was iden-
tiﬁed as bipolar based on a BP diagnosis claim and/or a
mood stabilizer claim. Of these BP patients, unrecognized
BP (UBP) patients received their initial BP diagnosis
and/or mood stabilizer (MS) prescription after AD initi-
ation, while recognized BP (RBP) patients had these
records on/before AD initiation. Medical costs are total
payments to providers; indirect costs are payments to
employees for lost work time. RESULTS: BP patients
accounted for 7.0% of the research sample (3.7% UBP,
3.3% RBP). UBP patients incurred signiﬁcantly more
monthly medical costs in the 12 months following initia-
tion of AD treatment than RBP patients, for both non-BP
treatment costs ($1081 versus $683) and total medical
costs ($1179 versus $802). MDD total medical costs
($585) were signiﬁcantly lower than both RBP and UBP
costs. In the 6 months before the Index Date, UBP and
RBP patient monthly costs for medical care other than BP
treatment were similar ($542 versus $504, respectively).
MDD total medical costs ($436) were signiﬁcantly lower
than RBP total costs ($631), but not UBP total costs
($542). Monthly indirect costs are signiﬁcantly greater for
UBP and RBP employees compared to MDD employees
in the 12 months following the Index Date ($570, $514,
and $335, respectively). CONCLUSIONS: Accurate and
timely recognition of BP disease is associated with lower
overall medical costs and lower indirect work loss costs.
More effort is needed to quickly diagnose and effectively
treat patients with bipolar disorder.
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OBJECTIVE: To compare the mental health resource use
associated with risperidone, olanzapine, and quetiapine
for treatment of bipolar disorder in a real-world setting.
METHODS: This was a retrospective, comparative study
based on claims data compiled from several US health
plans from 1999 to early 2002. Antipsychotic treatment
episodes were constructed to more accurately identify
mental health resources associated with risperidone, 
olanzapine, and quetiapine. Selection bias was reduced 
by focusing only on episodes involving antipsychotic
monotherapy and for which the patient did not switch
from a prior antipsychotic. The primary measure ana-
lyzed was non-antipsychotic mental health care charges
per patient per month (PPM), deﬁned as total mental
health care charges excluding antipsychotic drug charges
during treatment episodes with risperidone, olanzapine,
or quetiapine. To control for differences in patient 
characteristics, regression models combining risperidone,
olanzapine, and quetiapine treatment episodes were esti-
mated to determine their effects on non-antipsychotic
mental health resource use. RESULTS: Regression esti-
mates showed that quetiapine was associated with the
lowest non-antipsychotic mental health care charges
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PPM. These charges averaged about $14 PPM (P = 0.069)
and $9 PPM (P = 0.231) lower than those of risperidone
and olanzapine, respectively, a savings of 2%–3% based
on a $526 PPM mean charge. Differences in non-
antipsychotic mental health care charges PPM among
bipolar patients treated with risperidone, olanzapine, or
quetiapine were largely explained by differing patient and
treatment characteristics rather than the antipsychotic
used. After dosage levels were standardized, however,
olanzapine was associated with signiﬁcantly higher drug
acquisition costs than those of risperidone and quetiap-
ine (57% and 49% respectively; P < 0.01). Although the
difference in drug charges between risperidone and que-
tiapine was not statistically signiﬁcant, quetiapine was
associated with lower PPM resource utilization. CON-
CLUSION: Quetiapine appears to be associated with
modestly lower non-antipsychotic mental health resource
use compared to risperidone and olanzapine for treatment
of bipolar disorder.
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OBJECTIVE: This study compared treatment patterns for
bipolar disorder (BP) patients (recognized and unrecog-
nized) to those of major depression disorder (MDD)
patients without a BP claim (non-BP) during the obser-
vational period. METHODS: An employer administrative
claims database (covering several managed care health
plans from 1998–2001) was used to identify 11,464
patients diagnosed with MDD and initially treated with
antidepressants (AD). Of these, unrecognized BP (UBP)
patients received their initial BP diagnosis and/or mood
stabilizer (MS) prescription after AD initiation, while rec-
ognized BP (RBP) patients had these records on/before
AD initiation. Induced BP patients were deﬁned as those
manifesting mania within six months after starting AD.
RESULTS: BP patients accounted for 6.8% of the
research sample (3.7% UBP and 3.1% RBP). Induced BP
represented 6.6% of all BP patients. RBP patients had a
slightly lower rate of induction (6.2%) than UBP patients
(6.9%). The use of combination therapies varied in the
non-BP, UBP, and RBP patients (11%, 32%, and 43%,
respectively) (all pairwise p < 0.01). The use of MS was
less frequent among UBP than RBP patients (14% and
34%, respectively) (p < 0.0001). CONCLUSIONS: A
substantial number of AD-treated MDD patients could be
classiﬁed as bipolar (either RBP or UBP), and were at risk
for induction of mania. RBP and UBP patients initiated
with more combination therapies, as compared to Non-
BP patients. MS use increased when BP was recognized.
More effort is needed to quickly diagnose and effectively
treat BP patients.
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OBJECTIVES: A Markov model was developed to deter-
mine costs and outcomes of one year of antipsychotic
treatment for patients with schizophrenia. METHODS:
The model simulated a 4-armed, randomized, parallel,
12-month observational study of 2000 inpatients and
2000 outpatients initiating treatment on ziprasidone (Z),
risperidone (R), olanzapine (O), or haloperidol (H).
Equivalent efﬁcacy between treatments was assumed;
however, relapse rates on haloperidol were adjusted to be
consistent with Csernansky et al. 2002. Weighted aver-
ages were used for published treatment-emergent adverse
event rates for akathesia (Z = 7.9, R = 15.1, O = 7.8, H
= 20.8), other extrapyridimal symptoms (Z = 11.5, R =
9.0, O = 11.6, H = 26.7), weight gain (Z = 10.0, R = 14.8,
O = 28.2, H = 11.0), and prolactin-related side effects (Z
= 2.2, R = 11.2, O = 5.2, H = 3.0) to estimate tolerabil-
ity, concomitant medication use, treatment changes, 
non-compliance, and relapse. Costs for inpatient care,
sub-acute chronic care, and outpatient visits were based
on published private and public medical claims databases.
Medication costs were $170.63/month (Z = 120mg/d),
$242.61/month (R = 4.8mg/d), $344.17 (O = 13.2mg/d),
and $6.72 (H = 15mg/d) (RedBook 2002). Outcome mea-
sures included days in acute care, total direct medical
costs, and incremental costs. RESULTS: Because of
greater tolerability, estimated days in acute care were
lowest for ziprasidone (42.4) when compared to olanza-
pine (42.8), risperidone (43.1), or haloperidol (53.6). Due
to lower estimated days in acute care and lower mainte-
nance treatment drug costs, estimated annual total health-
care costs for each drug cohort (n = 1000 patients per
cohort) were lowest for those patients initiating treatment
with ziprasidone vs. risperidone (+$787,000), olanzapine
(+$964,000), or haloperidol (+$4,210,000). Sensitivity
analyses to changes in model assumptions for adverse
event, adherence, and relapse rates, and healthcare 
costs were robust to these conclusions. CONCLUSION:
Ziprasidone has an adverse event proﬁle distinct from
those of other atypical antipsychotics and lower pharma-
ceutical acquisition costs, which potentially lead to
improved outcomes and lower total direct costs.
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